When I started my working life in a pediatric intensive care unit, I could not possibly have imagined that, 30 years later, I would be living through a phenomenal scientific revolution in which we are using mRNA to give the instructions a cell uses to make proteins. Even as recently as 2003, when the human genome was cloned and we were all brimming with curiosity about what it meant for DNA-based therapies, I do not think we realized that mRNA therapeutics would prove so attractive.
The beauty of mRNA therapy is that it acts locally and transiently. We are not trying to integrate it into a persons genome, as we would with DNA, and make a permanent change. What we are doing is trying to accelerate and improve what the body does on its own.
With VEGF-A mRNA in heart failure, we are aiming to boost the bodys own healing mechanisms. We know, for example, that the body produces more VEGF-A after a heart attack to try and prevent heart muscle damage. We have also seen that there is a fine line between the amount of muscle damage that has very little effect on a patients life and the amount that leaves them waking up at night short of breath and unable to live normally.
Our preclinical and pathophysiological models suggest that, following a heart attack, a single intervention could have the potential to allow a patient to produce enough VEGF-A, for long enough after an injection, to enable them to self-heal and not be left with potentially life-changing heart failure.
Injecting someone with mRNA very precisely into their heart after a heart attack may sound scary. But cardiologists already routinely put drug-eluting stents into the coronary arteries and carry out bypass surgery. We expect such targeted treatment will not be a barrier to mRNA therapy for heart failure.
Modernas collaboration with AstraZeneca to discover and develop a potential mRNA therapy for heart failure has been very productive, as our teams have a shared sense of mission and urgency but complementary skills and competencies. At Moderna, we have had success in producing our mRNA with the right process and purity so that the immune cells did not see them as invader and attack them, while AstraZenecas expertise in drug delivery and cardiovascular medicine has enabled VEGF-A mRNA therapy to move into clinical trials.
To successfully get mRNA therapies into cells, we have worked through a lot of research steps. These have included optimising the chemistry of the mRNA and the way we make it and formulating it into a drug that gets through cell membranes. No single advance has provided all the answers, and we have needed a pharmaceutical engineering mind-set to work out how to solve all the problems. The good news is that, like digital software, our optimized mRNA platform is highly reproducible and we can use it again and again to make mRNAs for different proteins.
In collaboration with AstraZeneca, we are now moving ahead with the development of a relaxin mRNA for the treatment heart failure. Relaxin is a natural hormone that works during pregnancy to enable a womans cardiovascular system to adjust to her need for increased blood volume and cardiac output. We want to use mRNA to boost production of relaxin in people with heart failure to achieve a similar effect in increasing cardiac output to meet the bodys needs. A recombinant protein form of relaxin has already been tested in heart failure but failed to improve outcomes. We believe that this is because relaxin has a short half-life, and it is not practical to infuse it for a long enough period to achieve the required effects. We want to develop an mRNA which results in production of a form of relaxin that has an extended half-life so tissue exposure will be longer and, hopefully, will result in a clinical benefit.
In the longer term, we envision patients being given combinations of mRNA therapies to treat cardiovascular and other diseases. As scientists, we tend to take a reductionist approach to treatment whereby we address one target at a time. But the body does not work like that. It is continually using dozens of mRNAs to simultaneously make dozens of proteins. Based on our experience at Moderna of using multiple mRNAs for vaccines, we believe that it should be relatively straightforward to extend that approach and combine mRNAs for future drug therapies. The challenge will come in choosing the right combination, in the right ratio.
As we move forward with mRNA therapies, our main priority should be to marry the exciting scientific innovations we are making with the unmet clinical needs that are still, in the real world, leading to significant numbers of deaths and limiting peoples lives.
Find out more about Cardiac Regeneration
See the rest here:
Entering a new era in vascular and cardiac regeneration ...
- Cardiac Regeneration - Center for Regenerative Medicine - Mayo Clinic ... - April 11th, 2018 [April 11th, 2018]
- Cardiac Regeneration - Mayo Clinic - April 22nd, 2018 [April 22nd, 2018]
- Materials - MDPI - May 18th, 2018 [May 18th, 2018]
- Cardiac Stem Cell Research - Cedars-Sinai - May 22nd, 2018 [May 22nd, 2018]
- Cardiac regeneration: current therapiesfuture concepts ... - May 26th, 2018 [May 26th, 2018]
- Cardiac Regeneration - Victor Chang Cardiac Research Institute - May 30th, 2018 [May 30th, 2018]
- Cardiology Conferences | Cardio 2018 Events | Cardiac ... - June 6th, 2018 [June 6th, 2018]
- Laboratory for Cardiac Regeneration | Baylor College of ... - June 18th, 2018 [June 18th, 2018]
- Regeneration of Muscle - July 8th, 2018 [July 8th, 2018]
- Regeneration of Muscle - eLS: Essential for Life Science - July 14th, 2018 [July 14th, 2018]
- Cardiac Repair and Regeneration Research Unit | Heart and ... - July 25th, 2018 [July 25th, 2018]
- Myogenesis - Wikipedia - August 8th, 2018 [August 8th, 2018]
- Regeneration (biology) - Wikipedia - August 21st, 2018 [August 21st, 2018]
- World Cardiology and Cardiologist Meeting - August 21st, 2018 [August 21st, 2018]
- Cardiac (comics) - Wikipedia - August 26th, 2018 [August 26th, 2018]
- Cardiac regeneration and repair - 1st Edition - Elsevier - September 21st, 2018 [September 21st, 2018]
- Post-doc position available cardiac regeneration ... - September 29th, 2018 [September 29th, 2018]
- UW Bioengineering: Building World Leadership in Heart ... - September 29th, 2018 [September 29th, 2018]
- Cardiac Regeneration - What Science Can Do - AstraZeneca - October 2nd, 2018 [October 2nd, 2018]
- Cardiac Regeneration, Stem Cells | Research | Baylor ... - November 30th, 2018 [November 30th, 2018]
- Cardiac Regeneration - Victor Chang Institute - December 6th, 2018 [December 6th, 2018]
- Cardiac regeneration and repair - 1st Edition - December 19th, 2018 [December 19th, 2018]
- Heart Regeneration Technologies - December 19th, 2018 [December 19th, 2018]
- Cardiac Regeneration - Center for Regenerative Medicine ... - December 19th, 2018 [December 19th, 2018]
- Zebrafish Heart Regeneration | HHMI BioInteractive - December 22nd, 2018 [December 22nd, 2018]
- Rapid cell regeneration - Heroes Wiki - December 22nd, 2018 [December 22nd, 2018]
- Cardiac muscle - Wikipedia - December 23rd, 2018 [December 23rd, 2018]
- Cardiac regeneration in and : discrepancies and problems ... - January 8th, 2019 [January 8th, 2019]
- OHSU Center for Regenerative Medicine Heart Regeneration ... - January 8th, 2019 [January 8th, 2019]
- Dr. Sanjiv Dhingra, Cardiac Regeneration and Tissue ... - January 30th, 2019 [January 30th, 2019]
- Mending a Broken Heart: Stem Cells and Cardiac Repair ... - February 20th, 2019 [February 20th, 2019]
- Cardiac Repair and Regeneration | Division of Cardiology ... - February 20th, 2019 [February 20th, 2019]
- Stem Cell Therapy and Stem Cell Injection Provider Finder ... - March 5th, 2019 [March 5th, 2019]
- KearnsSayre syndrome - Wikipedia - March 8th, 2019 [March 8th, 2019]
- Ruohola-Baker Lab - March 15th, 2019 [March 15th, 2019]
- MTS Science - May 3rd, 2019 [May 3rd, 2019]
- New Insights Into the Healing Capacity of the Heart: The Hippo Pathway - Cath Lab Digest - September 26th, 2019 [September 26th, 2019]
- Conjugated polymers optically regulate the fate of endothelial colony-forming cells - Science Advances - September 29th, 2019 [September 29th, 2019]
- The nanoengineer working to mend broken hearts - UNSW Newsroom - September 29th, 2019 [September 29th, 2019]
- New insights into heart's healing capacity - Baylor College of Medicine News - September 29th, 2019 [September 29th, 2019]
- Tenaya Therapeutics Closes $92 Million Series B Financing - BioSpace - October 5th, 2019 [October 5th, 2019]
- Regenerative medicine today: Are diabetes and vascular disease treatments ready for the clinic? - Science Magazine - October 5th, 2019 [October 5th, 2019]
- Reviewing resTORbio Inc. (TORC)'s and Anika Therapeutics Inc. (NASDAQ:ANIK)'s results - MS Wkly - October 14th, 2019 [October 14th, 2019]
- TAMassociati: the new Church of the Resurrection in Varignano - Floornature.com - October 14th, 2019 [October 14th, 2019]
- What the Hippo pathway in cardiac fibroblasts reveals about heart function - Baylor College of Medicine News - October 19th, 2019 [October 19th, 2019]
- Capricor Therapeutics to Host Key Opinion Leader Call on the Role of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (DMD) - BioSpace - October 22nd, 2019 [October 22nd, 2019]
- Regenerative Medicine Market Industry Outlook, Growth Prospects and Key Opportunities - Health News Office - October 24th, 2019 [October 24th, 2019]
- Ottawa-based treatment a leap forward in addressing heart failure - Winnipeg Sun - October 27th, 2019 [October 27th, 2019]
- Global Regenerative Medicines Market Demand Analysis & Opportunity Evaluation Report 2019-2027 with Focus on U.S. & Europe -... - November 15th, 2019 [November 15th, 2019]
- The Heart of the Matter: Leveraging Advances in Cardiac Biology to Innovate Gene-Based Therapies for Heart Failure - Physician's Weekly - November 15th, 2019 [November 15th, 2019]
- SANUWAVE Health Reports Third Quarter 2019 Financial Results Other OTC:SNWV - GlobeNewswire - November 16th, 2019 [November 16th, 2019]
- Moderna: Undervalued As The Promising Pipeline Awaits Collaborations - Seeking Alpha - November 23rd, 2019 [November 23rd, 2019]
- Comparative Study of the Therapeutic Potential of Mesenchymal Stem Cells Derived from Adipose Tissue and Bone Marrow on Acute Myocardial Infarction... - November 23rd, 2019 [November 23rd, 2019]
- Stem Cell Therapy May Improve Heart Health In New Ways - TheHealthMania - December 5th, 2019 [December 5th, 2019]
- AgeX Therapeutics Issues Year-End Letter to Shareholders - BioSpace - December 9th, 2019 [December 9th, 2019]
- Polymeric Biomaterials Market Trends Analysis Forecast to 2019-2024 |Evolving Industry Overview by Types, Applications, Size & Share - Sino News... - December 16th, 2019 [December 16th, 2019]
- SMD - Researchers look behind the biological curtain on how fish oil might fight inflammatory disease - QMUL - December 16th, 2019 [December 16th, 2019]
- Suspended animation, you say? The biggest and freakiest scientific breakthroughs of 2019 - SYFY WIRE - December 29th, 2019 [December 29th, 2019]
- 2019: Year in Pictures by Robert Cohen | Metro - STLtoday.com - December 31st, 2019 [December 31st, 2019]
- MicroCures Announces Issuance of New Patent Covering First-of-its-Kind Cell Movement Decelerator Technology with Potential Applications in Oncology... - January 15th, 2020 [January 15th, 2020]
- Cells that regenerate heart in zebrafish discovered - Biology Reporter - February 7th, 2020 [February 7th, 2020]
- SANUWAVE Health Appoints Dr. Tom Price to Its Board of Directors - Yahoo Finance - February 7th, 2020 [February 7th, 2020]
- Capricor Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update - Associated Press - March 19th, 2020 [March 19th, 2020]
- Researchers and Doctors alike pursuing the field of stem cell research in treating heart attack survivors - Medical Herald - March 19th, 2020 [March 19th, 2020]
- Artificial Heart Lung Machines Market report reviews opportunities and analysis by size, share, trends, manufacturer, forecast 2020-2026 - WhaTech... - April 29th, 2020 [April 29th, 2020]
- Scientists have figured out how to make the heart to regenerate - The Times Hub - April 29th, 2020 [April 29th, 2020]
- Gene therapy for follistatin mitigates systemic metabolic inflammation and post-traumatic arthritis in high-fat dietinduced obesity - Science Advances - May 9th, 2020 [May 9th, 2020]
- SANUWAVE HEALTH : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) - marketscreener.com - May 15th, 2020 [May 15th, 2020]
- SANUWAVE Health to Hold First Quarter Financial Results and Business Update Call on Monday, May 18, 2020 - Yahoo Finance - May 15th, 2020 [May 15th, 2020]
- SANUWAVE Health to Hold Investor Live Webcast on Wednesday, June 10, 2020 - Yahoo Finance - June 10th, 2020 [June 10th, 2020]
- SANUWAVE Health Enters Into Exclusive Letter of Intent to Acquire Celularity's UltraMIST and Exclusive Partnership Rights for Wound Care Biologic... - June 11th, 2020 [June 11th, 2020]
- SANUWAVE Health, Inc. Discusses The Potential of Their Celularity Acquisition with The Stock Day Podcast (SNWV) July 1, 2020 - Stock Day Media - July 1st, 2020 [July 1st, 2020]
- Interim Analysis of Recardio's Phase II Clinical Trial to Be Presented at the 2020 Congress of the European Society of Cardiology - PRNewswire - July 1st, 2020 [July 1st, 2020]
- Growth and demand of Plasma Therapy in the Asia Pacific Region available in the latest report - WhaTech Technology and Markets News - July 4th, 2020 [July 4th, 2020]
- Plasma Therapy Market Size by Top Companies, Regions, Types and Application, End Users and Forecast to 2027 - Bulletin Line - August 14th, 2020 [August 14th, 2020]
- Generex Biotechnology Subsidiary Olaregen Therapeutix Announces Publication on the Use of Excellagen for Vascular Repair - BioSpace - August 14th, 2020 [August 14th, 2020]
- Polymeric Biomaterials Market Insights by Current Trends 2020 Future Demand by Top Key Players, Regions, Industry Size, and Business Strategy... - September 11th, 2020 [September 11th, 2020]
- CORRECTION - SANUWAVE Health Announces Reimbursement Coverage for BIOVANCE From Largest Medicare and Medicaid Administrator in U.S. - Stockhouse - September 11th, 2020 [September 11th, 2020]
- New Research Paper Suggests RegeneRx's Thymosin Beta 4 May be Useful in Treating COVID-19 - PRNewswire - September 11th, 2020 [September 11th, 2020]
- To Repair a Damaged Heart, Three Cells are Better Than One - SDSU Newscenter - September 11th, 2020 [September 11th, 2020]